The antifibrotic field is at an inflection point: Madrigal’s Resmetirom secured the first-ever MASH approval in 2024, Boehringer’s nerandomilast hit its Phase 3 endpoint in IPF, and pharma giants like Lilly and GSK are investing billions in fibrosis pipelines.

Time: 8:30 AM – 3:30 PM

Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Ahmed Mousa, Chief Executive Officer, Vicore Pharma, Anna Zagorska, Director, Inflammation and Fibrosis, Gilead Sciences, and more